Edinburgh, Scotland, January 17, 2023 /PRNewswire/ — Green Bioactives Limited (“GBL”), a global leader in the discovery, development and sustainable production of high-value natural products derived from plant cell cultures, announces the expansion of its leadership as it continues to evolve its business. Chris Meaney joins as Chief Business Officer (CBO) and Dr. Andy Hall-Ponselé as Head of Operations.
These appointments follow GBL’s successful £2.6 million seed financing round in December 2022. The company’s platform provides much-enhanced and sustainable access to the huge, diverse and valuable library of bioactives generated by the world’s plant population – natural products that are vital to the pharmaceutical, agricultural and food industries, but often difficult to be produced sustainably or economically using traditional manufacturing approaches.
David McElroyCEO of Green Bioactives, said: “I am extremely pleased with the strength and depth of the management team we are assembling to capitalize on the recent successes of Green Bioactives. Our unique offering has already generated considerable interest from business partners, and the track record of Chris and Andy’s proven performance and our leadership in biotech start-ups will enable us to capitalize on this potential and achieve our goal of becoming the world’s leading provider of safe, natural and sustainably-sourced plant-based products. .”
Chris Meaney
Chris brings to Green Bioactives over 18 years of business development experience in healthcare, nutraceuticals and manufacturing. Chris spent 12 years with Cambridge Nutraceuticals, from inception through commercial maturity in marketing and as business development manager, and was heavily involved in the creation of numerous product formulations.
Chris joins GBL from Primal Nutrition Solutions, a global manufacturer and supplier of vitamins and minerals, where he held the position of European Business Development Manager, responsible for launching the business in the European market. As Chief Commercial Officer, with his proven success in growing domestic and international businesses, Chris will lead efforts to secure new industry-specific business partnerships and increase product marketing and sales as Green Bioactives continues to grow.
Chris holds a BA in Business Studies from Liverpool John Moores University and has also held positions with Lloyds Pharmacy, Dexcel Pharma and Vivo Healthcare.
Andy Hall-Ponselé, DPhil
Andy joins GBL as Head of Operations and brings significant biotechnology, commercial and operational expertise to the company. In 2015 Andy co-founded Biotangents Ltd based on his expertise in synthetic biology and DNA assembly technology. Andy led the company as CEO in its first 18 months, secured funding and led its business strategy before becoming Chief Operating Officer, playing a key role in determining business development and go-to-market strategies. company products and in growing the company to 23 FTEs.
With his background in plant science and experience building Biotangents, Andy brings both scientific expertise and operational know-how to Green Bioactives. Andy will be responsible for growing GBL’s operational capabilities, enabling the company to demonstrate its biomanufacturing approach on a larger scale.
Andy holds a Ph.D. University of Oxford, where he explored genetic engineering to increase the abundance of secondary metabolites in tobacco cells. Andy also holds a BSc in Biotechnology from Edinburgh University and he previously worked as a scientist at synthetic biology start-up Genabler Ltd.
About green bioactives
Green Bioactives (“GBL”) is a world leader in the commercial use of plant vascular stem cells, which has enabled it to create a reliable and economically attractive platform for the sustainable biomanufacturing of plant biomolecules for commercial applications in cosmetics. , pharmaceutical, food and agricultural industries.
GBL’s platform provides much-enhanced and sustainable access to the huge, diverse and valuable library of bioactives generated by the world’s plant population – natural products that are vital to the pharmaceutical, agricultural and food industries, but often difficult to produce. sustainably or economically using traditional methods. manufacturing approaches. The company is currently working with several world-renowned partners.
GBL’s capabilities extend from the initial isolation of bioactive producer plant cells to the delivery of the final purified product. GBL’s knowledge of plant vascular stem cells also offers the company the opportunity to develop new approaches that meet the global need for sustainable and more efficient food production.
GBL was founded in 2020 and is currently based at the Roslin Innovation Center, Edinburgh, ScotlandUK.
For more information visit: www.green-bioactives.com
CONTACTS
Green bioactives
David McElroyCEO
info@greenbioactives.com
MEDISTRAV Consulting
David Dible, Eleanor Perkin, Sandi GreenwoodGeorge Underwood
GreenBioactives@medistrava.com
Tel: +44 203 928 6900
SOURCE Green Bioactives Limited